dc.contributor
Institut Català de la Salut
dc.contributor
[Heesen C] Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center, Hamburg, Germany. Department of Neurology, University Medical Center, Hamburg, Germany. [Röver C, Salem S, Heinz J] Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany. [Chard D] Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. [Rio J] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Multiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Heesen, Christoph
dc.contributor.author
Röver, Christian
dc.contributor.author
Salem, Susanna
dc.contributor.author
Heinz, Judith
dc.contributor.author
Chard, Declan
dc.contributor.author
Rio, Jordi
dc.date.accessioned
2025-10-24T10:34:15Z
dc.date.available
2025-10-24T10:34:15Z
dc.date.issued
2024-12-27T12:00:37Z
dc.date.issued
2024-12-27T12:00:37Z
dc.date.issued
2024-10-24
dc.identifier
Heesen C, Röver C, Salem S, Heinz J, Chard D, Rio J, et al. Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis—A systematic review and meta-analysis. Mult Scler J - Exp Transl Clin. 2024 Oct 24;10(4):20552173241274616.
dc.identifier
https://hdl.handle.net/11351/12357
dc.identifier
10.1177/20552173241274618
dc.identifier
001346432800001
dc.identifier.uri
http://hdl.handle.net/11351/12357
dc.description.abstract
Multiple sclerosis; Disease-modifying therapy; Treatment response
dc.description.abstract
Esclerosi múltiple; Teràpia modificadora de la malaltia; Resposta al tractament
dc.description.abstract
Esclerosis múltiple; Terapia modificadora de la enfermedad; Respuesta al tratamiento
dc.description.abstract
Abstract
Background
This meta-analysis aimed to assess the treatment effects of immunotherapies in subgroups of adults with clinically isolated syndrome or relapsing forms of multiple sclerosis (MS) and the effect of potential treatment effect modifiers (TEMs).
Methods
Phase 2 and 3 RCTs with a placebo comparator were analyzed. Risk of bias was assessed. Random-effects meta-analyses were conducted to summarize treatment effects within subgroups and differences in treatment effects between subgroups.
Results
Thirty-one studies were included. Age < 40 years was the strongest TEM for relapse rate across DMTs with a ratio of rate ratios (RRR) of 1.44 (95% CI 1.09–1.90; 7 studies). Disability progression was influenced by age (ratio of hazard ratios, RHR 1.59, 95% CI 1.11–2.29; 4 studies). Dichotomizing patients based on EDSS cut-offs (EDSS 2.0 and 3.0) also showed a significantly higher benefit for those less disabled for relapse rate (RRR 1.35, CI 1.03–1.76; 8 studies). Sex, baseline MRI parameters, previous immunotherapy, and clinical presentation showed no effect in this meta-analysis.
Conclusion
Age < 40 is a robust TEM for a lower relapse rate as well as less disability progression across six MS immunotherapies. Additionally, a lower baseline EDSS was predictive of the relapse rate.
dc.description.abstract
This work was supported by the Federal Ministry of Education and Research (grant number 01KG1804).
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Multiple Sclerosis Journal - Experimental, Translational and Clinical;10(4)
dc.relation
https://doi.org/10.1177/20552173241274618
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Immunoteràpia
dc.subject
Medicaments - Efectes fisiològics
dc.subject
Resposta immunitària - Regulació
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis—A systematic review and meta-analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
